|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 60.26 Million
|
|
CAGR (2025-2030)
|
4.35%
|
|
Fastest Growing Segment
|
Gene Augmentation
|
|
Largest Market
|
Northern & Central
|
|
Market Size (2030)
|
USD 76.91 Million
|
Market Overview
The Saudi Arabia gene therapy market was valued at USD 60.26 million in 2024 and is projected to reach USD 76.91 million by 2030, growing at a CAGR of 4.35% during the forecast period.
Saudi Arabia faces a high prevalence of genetic disorders due to common consanguineous marriages, leading to increased cases of thalassemia, sickle cell anemia, and cystic fibrosis compared to global averages. This growing burden has boosted interest in advanced treatments like gene therapy.
Awareness of gene therapy’s potential is rising among healthcare providers and patients as technological breakthroughs such as CRISPR-Cas9 gene editing and improved delivery systems enhance feasibility and effectiveness. These innovations are accelerating commercialization and expanding clinical applications, offering hope for curing previously untreatable conditions.
As healthcare infrastructure advances, gene therapies are expected to become more accessible and affordable, driving market growth. However, high treatment costs remain a major barrier, particularly for rare diseases, limiting access for patients without comprehensive insurance coverage.
Key Report Takeaways
- Gene augmentation was the fastest growing type in 2024, driven by high prevalence of inherited disorders such as sickle cell disease and thalassemia that require durable treatment options.
- Oncological diseases lead by application during the forecast period, as gene therapy targets tumor driving mutations and supports immune based approaches. Advances such as CRISPR Cas9 gene editing enable more precise and personalized cancer treatment strategies with reduced off target effects.
- Northern and Central regions dominate, led by Riyadh’s concentration of research hospitals, clinical trial centers, and molecular medicine expertise. Strong academic networks and skilled specialists support adoption of complex gene therapy platforms.
- Key players include Vertex Pharmaceuticals (Europe) Limited, CRISPR Therapeutics AG, Merck Limited, Medical Business Center Co., and Salehiya Medical.
Key Market Drivers
Epidemiological and Demographic Drivers
The gene therapy market in Saudi Arabia is anchored in an epidemiological profile where inherited and rare genetic disorders have a higher clinical footprint, making gene-based interventions more relevant for well-defined patient groups. Long-standing patterns of consanguineous marriage and larger family structures increase the probability of autosomal recessive disorders and other monogenic diseases, which often have limited conventional options beyond chronic supportive care.
For instance, according to a Journal of Medical Genetics study of 3,212 Saudi families, 57.7% of marriages in the sample were consanguineous, including 28.4% first-cousin marriages, a structure that can elevate inherited-disease risk and expand the pool of patients who could benefit from advanced genetic medicines. The same underlying burden also supports a broader long-term pipeline, because it builds demand for earlier diagnosis, precision targeting, and therapies that can shift care from lifelong management to disease modification.
Healthcare Infrastructure and Ecosystem Development
Saudi Arabia’s push to expand and modernize healthcare delivery is a critical enabler for gene therapy because these treatments require specialized infusion capacity, advanced diagnostics, intensive monitoring, and multidisciplinary care teams that are typically concentrated in tertiary settings. Hospital scale and workforce depth matter because they determine how quickly complex protocols can be adopted, standardized, and expanded beyond a few flagship centers.
For instance, according to the General Authority for Statistics Healthcare Establishments and Workforce Statistics Publication 2024, Saudi Arabia had 516 hospitals in 2024, 23.4 hospital beds per 10,000 population, and 129,772 physicians, alongside 5,779 primary healthcare centers and medical complexes, which signals the system capacity needed to support referral networks, confirmatory testing pathways, and post-therapy follow-up.
These infrastructure gains also strengthen the supporting ecosystem for advanced therapies, including quality systems, specialty pharmacies, and cold-chain capable logistics that reduce operational risk when delivering high-value, time-sensitive biologic products.
Technological and Scientific Advancements
Genomics and molecular diagnostics are accelerating gene therapy readiness in Saudi Arabia because they improve mutation identification, patient stratification, and clinical decision-making around who is eligible and when to intervene. National-level genomic programs and databases also help quantify local variant frequencies, which supports better disease mapping and improves the ability to design or adapt protocols for Saudi populations.
For instance, according to the Saudi Vision 2030 Saudi Genome Program project page, the program has processed 63,000 samples, identified 7,500 pathogenic variants, and is supported by seven Saudi centers working in collaboration with more than 100 researchers, indicating expanding national capability in population genomics and bioinformatics. This type of structured genomic infrastructure supports earlier diagnosis and more precise eligibility workflows, both of which are prerequisites for scaling gene therapy beyond pilot use into routine specialist pathways.
Investment, Partnerships, and Market Readiness
Saudi Arabia is also strengthening market readiness through investment and partnership frameworks that prioritize biotechnology, localization, and advanced medical innovation as part of economic diversification and health security goals. Public-sector strategy matters in gene therapy because it can unlock capital for manufacturing capability, workforce development, and technology transfer while shaping reimbursement and access models for high-cost, one-time interventions.
For instance, according to the Saudi Vision 2030 National Biotechnology Strategy page, the strategy aims to establish Saudi Arabia as the leading biotech hub in MENA by 2030 and globally by 2040, and it targets creation of 11,000 high-quality job opportunities by 2030, with strategic focus areas that include vaccines, biomanufacturing, and genomics. According to a Saudi Ministry of Health update on the strategy, the plan also targets over 11,000 specialized jobs by 2030 growing to 55,000 by 2040, and it explicitly includes driving genomic and gene therapy research as a strategic pillar, which supports a stronger operating environment for partnerships, clinical adoption, and longer-term localization.
Download Free Sample Report
Key Market Challenges
High Treatment Costs
The
development of gene therapies involves extensive research, rigorous clinical
trials, and high costs associated with the development of new drugs. The
process of developing gene therapies, which often includes modifying or
replacing faulty genes to treat diseases, requires advanced technologies and
highly specialized expertise. These R&D activities demand considerable
investment in time and resources, which are passed on to patients once the
therapy is commercialized. The expensive nature of R&D for gene therapies
poses a challenge to both manufacturers and healthcare systems, particularly in
markets like Saudi Arabia where the overall healthcare budget can face
constraints.
Gene
therapy manufacturing is complex and costly, involving highly specialized
facilities, sophisticated equipment, and skilled personnel. The production of
gene therapies typically requires the use of viral vectors to deliver genetic
material, and this process is intricate and requires strict quality controls to
ensure safety and efficacy. The need for personalized therapies, which are tailored
to individual patients, further escalates the cost of production. The high
manufacturing costs not only impact the price of the treatment but also create
barriers to scaling up production to meet increasing demand, limiting the
number of patients who can access these therapies in Saudi Arabia.
Gene
therapies are subject to stringent regulatory requirements to ensure patient
safety and therapeutic effectiveness. In Saudi Arabia, as in other countries,
the approval and regulation of gene therapies are governed by rigorous
standards set by the Saudi Food and Drug Authority (SFDA) and other relevant
health authorities. Meeting these regulations involves additional costs related
to compliance, testing, and approval processes, further driving up the overall
price of gene therapies. These regulatory hurdles can delay the introduction of
new treatments into the market, limiting their availability to patients and
placing an additional financial burden on healthcare systems.
Key Market Trends
Increased Focus on Personalized Medicine
Personalized medicine is increasingly being recognized as a key strategy in improving patient outcomes, particularly in the treatment of complex and rare genetic disorders. GCC countries have acknowledged the significance of personalized medicine, with the King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Saudi Arabia pioneering genomics research alongside the massive Saudi Genome Program. It is anticipated that other institutions will follow suit.
In Saudi Arabia, the high prevalence of genetic disorders, which affect an estimated 8% of births, has contributed to the rising demand for targeted therapies that are customized to an individual’s genetic profile. Gene therapies, which aim to correct genetic mutations or introduce new genes to treat diseases, are a perfect fit for this approach.
By focusing on the genetic makeup of patients, personalized gene therapies can offer more precise and effective treatment options, improving the chances of successful outcomes. This is exemplified by new partnerships, such as the October 2025 joint venture between PGxAI and Najashi Holding to deploy an AI-powered pharmacogenomics platform in the Kingdom. The shift towards personalized care in Saudi Arabia is aligning with global healthcare trends, where patients and healthcare providers are increasingly seeking treatments that go beyond traditional approaches.
The country’s growing understanding of the benefits of personalized medicine is reflected in a nationwide study where 52.3% of clinicians reported that genetic tests helped them understand their patients' disorder risks. Combined with its substantial investments in healthcare infrastructure, this positions it as a strong contender in the global gene therapy market. The rise of personalized medicine in Saudi Arabia's gene therapy market is driven by significant advancements in genomic research and biotechnology.
With the increasing availability of genomic sequencing technologies, such as next-generation sequencing (NGS), healthcare providers are now able to identify genetic mutations more quickly and accurately. This is demonstrated by the Saudi Genome Program, which has processed over 63,000 samples and identified 7,500 pathogenic variants, allowing for a deeper understanding of diseases at the molecular level and making it easier to develop personalized treatment plans.
Segmental Insights
Type Insights
Based
on Type, Gene Augmentation have emerged as the fastest growing segment in the Saudi
Arabia Gene Therapy Market in 2024. One
of the primary drivers of the gene augmentation segment’s growth is the rise in
the number of genetic disorders in Saudi Arabia. The country has a
higher-than-average prevalence of inherited genetic conditions, such as sickle
cell disease, thalassemia, and other hemoglobinopathies, many of which are
treatable or manageable through gene augmentation techniques. These conditions,
which often require long-term management or even lifelong treatments, create a
compelling need for more permanent, curative solutions like gene augmentation.
The potential to offer life-changing or life-saving treatments for patients
with these genetic diseases has accelerated the adoption of gene augmentation
therapies.
Moreover,
Saudi Arabia’s commitment to advancing its healthcare system under Vision 2030
has led to significant investments in medical research, biotechnology, and the
development of cutting-edge therapies. This includes support for gene therapy
initiatives, where gene augmentation is at the forefront of innovation. As the
healthcare infrastructure in the kingdom continues to improve, more specialized
treatment centers and facilities are being established to offer these advanced
therapies, making gene augmentation more accessible to patients.
Application Insights
Based
on Application, Oncological Diseases have emerged as the fastest growing
segment in the Saudi Arabia Gene Therapy Market during the forecast period. One
of the primary reasons for the growth of oncological diseases within the gene
therapy market is the limitations of traditional cancer treatments, such as
chemotherapy, radiation, and surgery. While these methods remain essential,
they often come with significant side effects and limited effectiveness,
especially in advanced stages of cancer.
Gene therapy provides a potential
alternative by targeting the genetic mutations that drive cancer, offering a
more precise and potentially less toxic treatment approach. By modifying the
genetic makeup of cancer cells or boosting the body's immune system to better
fight cancer, gene therapy aims to address the root causes of cancer at a
molecular level.
Advancements
in gene editing technologies, particularly CRISPR-Cas9, have significantly
improved the ability to target cancer cells and correct genetic mutations that
cause or promote tumor growth. These innovations have made it possible to
develop gene therapies that can be tailored to individual patients, increasing
the effectiveness of treatments and minimizing side effects. The ability to
personalize cancer treatments based on a patient's genetic profile has created
new opportunities for gene therapy in oncology, contributing to its growth in
Saudi Arabia.
Download Free Sample Report
Regional Insights
Based
on Region, Northern & Central have emerged as the dominating region in the Saudi
Arabia Gene Therapy Market in 2024. The Northern and Central regions are home
to some of Saudi Arabia's largest and most advanced healthcare institutions,
particularly in cities like Riyadh, the capital. Riyadh is a central hub for
medical research, clinical trials, and the implementation of advanced
therapies. The concentration of specialized hospitals, medical universities,
and research centers in this region has fostered a conducive environment for
the development and adoption of gene therapies.
The
Northern and Central regions have a higher concentration of healthcare
professionals, researchers, and specialists in gene therapy and molecular medicine.
This skilled workforce is essential for advancing the adoption of gene therapy
technologies, as it facilitates the development, clinical testing, and
administration of gene therapies. The region’s robust educational and training
systems also contribute to an increasing talent pool in the field of gene
therapy.
Recent Development
- In October 2025, KFSHRC reported it had treated more than 200 patients with genetically modified T-cell therapy since 2020 and announced the launch of local manufacturing as part of expanding advanced therapy capabilities.
- In October 2025, SFDA published “Gene Therapy CMC Requirements for Clinical Trials” (Version 1.0), setting formal expectations for chemistry, manufacturing and controls documentation for gene-therapy clinical-trial submissions.
- In January 2025, one month after US regulators approved the first therapeutic use of CRISPR/Cas9 a gene therapy for sickle cell disease (SCD) and beta thalassemia the Kingdom of Saudi Arabia followed suit. Notably, Casgevy became the first drug to advance through the country's Breakthrough Medicines Program, underscoring the Saudi government's dedication to introducing cutting-edge therapeutics to a region with a higher prevalence of genetic disorders compared to Western countries.
- In
October 2024, King Faisal Specialist Hospital & Research Centre (KFSHRC)
achieved a significant milestone in cancer treatment with the initiation of
local CAR-T cell manufacturing, marking a groundbreaking medical advancement
for the Kingdom of Saudi Arabia. This strategic move has resulted in an 80%
reduction in therapy costs, from USD 0.35 million per patient to a more
affordable price. Building on this success, KFSHRC aims to scale its production
capacity to 100 gene therapies annually, broadening access to this cutting-edge
treatment for more patients. As a Platinum Sponsor at the Global Health
Exhibition, which opened today in Riyadh, KFSHRC highlights its expertise in
CAR-T cell production. The exhibition booth provides an in-depth overview of
the rationale behind local manufacturing, detailing the production process,
treatment mechanisms, and success stories, including remarkable outcomes in
cases of highly resistant leukemia and lymphoma.
Key Market Players
|
By Type
|
By Application
|
By Region
|
- Gene Augmentation
- Gene Silencing
- Others
|
- Oncological Diseases
- Genetic Diseases
- Cardiovascular Diseases
- Neuromuscular Diseases
- Hematological Diseases
- Infectious Diseases
- Others
|
- Eastern
- Western
- Northern & Central
- Southern
|
Report Scope
In this report, the Saudi Arabia Gene Therapy
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Saudi Arabia Gene Therapy Market, By Type:
o Gene Augmentation
o Gene Silencing
o Others
- Saudi Arabia Gene Therapy Market, By Application:
o Oncological Diseases
o Genetic Diseases
o Cardiovascular Diseases
o Neuromuscular Diseases
o Hematological Diseases
o Infectious Diseases
o Others
- Saudi Arabia Gene Therapy Market, By Region:
o Eastern
o Western
o Northern & Central
o Southern
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Saudi
Arabia Gene Therapy Market.
Available Customizations:
Saudi Arabia Gene Therapy Market report with the
given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Saudi Arabia Gene
Therapy Market is an upcoming report to be released soon. If you wish an early
delivery of this report or want to confirm the date of release, please contact
us at
[email protected]